A B S T R A C T A patient who had received multiple transfusions for complications of acute hemorrhagic pancreatitis developed a potent factor V anticoagulant with bleeding due to defective hemostasis. Despite its potency, the anticoagulant disappeared within 15 days of its first manifestation. A second patient with adenocarcinoma of the colon developed an anticoagulant to factor V postoperatively after a single blood transfusion. The anticoagulants appeared to react stoichiometrically with factor V in normal plasma in vitro. They had the physicochemical properties of immunoglobulins, and their activity was neutralized by antihuman immunoglobulin antiserum. One anticoagulant appeared to be slightly more active against homologous than against autologous factor V, but it also inhibited heterologous factor V. Both anticoagulants progressively inactivated intrinsic prothrombin activator formed from normal reagents in the incubation mixture of the thromboplastin generation test, thus confirming that factor V is required for the effective action of the intrinsic prothrombin activator. Since the anticoagulants were immunoglobulins whose activity was consumed in their reaction with factor V, consumption of anticoagulant activity was used to detect factor V antigenic material in test materials. Human serum without factor V clotting activity was found to consume anticoagulant activity, i.e., to contain inactive factor V antigenic material. Plasma from two patients with hereditary factor V deficiency (parahemophilia) failed to consume significant anticoagulant activity. Thus, the lack of factor V activity in these patients represents a deficiency of factor V molecules rather than the synthesis of a defective molecule with impaired clotting activity. 
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This paper is a report of studies on a much rarer anticoagulant, a potent inhibitor of factor V (proaccelerin), which was found in two patients. The mechanism of action and the properties of each patient's inhibitor were characterized. These inhibitors were used to study further the role of factor V in clotting and to define the defect in two patients with hereditary factor V deficiency (parahemophilia) (1) . METHODS 
Clotting methods
Platelet-poor plasma was prepared by high speed centrifugation of 9 volumes of venous blood added to 1 volume of a balanced citrate anticoagulant (2) . Plastic syringes and tubes were used. Serum was obtained by clotting blood in glass tubes and incubating the clotted blood for 2 hr at 370C.
Plasma and serum were used either fresh or after storage at -20'C in capped, plastic vials. Citrated saline was made by adding one part of 0.1 M trisodium citrate to five parts of 0.15 M sodium chloride, as described elsewhere (2) .
Factor V was measured in a one-stage system in which 0.1 ml of human brain thromboplastin (3), of either hereditary factor V deficiency plasma or normal plasma depleted of factor V (4) , and of test substance diluted in citrated saline were incubated together for 3 min at 370C and then clotted by adding 0.1 ml of 40 mm calcium chloride solution.
Modified thromboplastin generation test systems were utilized for some experiments. Citrated plasma was adsorbed with aluminum hydroxide gel as described previously (2) , and a cephalin reagent (5) was used in place of platelets. Details of these test systems are given in the Results section.
The following techniques were used in this laboratory for other clotting tests and have been described elsewhere: Quick prothrombin time (6) , prothrombin time by the P and P method (6), activated partial thromboplastin time (2), factor II (prothrombin) (5) modified by adding a serum reagent to supply factor X (Stuart-Prower factor), factor VII (proconvertin) (7), factor VIII (8), factor IX (plasma thromboplastin component) (9) , factor X (10), factor XI (plasma thromboplastin antecedent) (11) , and factor XII (Hageman factor) (12). Factor XIII was assayed qualitatively by observation of a fibrin clot incubated in 5 M urea at room temperature for 24 hr.
Clotting times were converted to per cent activity from dilution curves made with a pooled plasma from 11 normal subjects. The normal pooled plasma was stored at -20'C.
Immunological methods
Starch zone electrophoresis was performed by the technique of Kunkel (13) ; chromatography was performed on DEAE (diethylaminoethyl)-cellulose by the technique of Fahey and Horbett (14) ; and gel filtration was done on Sephadex G-200 (90 x 2.5 cm column) by the technique of Flodin and Killander (15) . IgG was digested with papain, and the Fab and Fc fragments were separated by chromatography on DEAE-cellulose as described by Franklin (16) . Protein concentration was determined either by a modified Folin technique (17) or by measuring absorbancy at 280 mju. Antigens were emulsified with an equal volume of complete Freund's adjuvant to give a final protein concentration of 2.5 mg/ml.
Antihuman immunoglobulin antiserum was prepared by hyperimmunizing rabbits to human Cohn fraction II which had been purified by passage through a DEAE column equilibrated with a phosphate buffer at pH 8.0 and ionic strength 0.01. The antiserum reacted strongly with K and X light-chains and with y chains. It reacted only very weakly with a chains and not at all with g chains. Since it reacted with both antigenic types of light chains, it reacted with all classes of human immunoglobulins and was, therefore, referred to as antihuman immunoglobulin antiserum.
Antiserum specific for IgG was made by absorbing the above antiserum with purified Fab fragment which had been prepared by papain digestion of purified Cohn fraction II.
Antiserum specific for IgM was made by hyperimmunizing rabbits with a macroglobulin purified from a patient with macroglobulinemia of Waldenstrbm. The patient's serum was dialyzed against distilled water; the resultant precipitate was dissolved in isotonic saline and applied to a Sephadex G-200 column equilibrated with 0.3 M NaCl; and the eluate from the first half of the first peak was concentrated by negative pressure in dialysis casing. This material gave a single line on immunoelectrophoresis with rabbit antihuman serum. The antiserum obtained with this antigen was absorbed with umbilical cord sera to make it specific for A chains.
Antiserum specific for IgA was prepared by hyperimmunizing rabbits with an IgA myeloma protein isolated from the serum of a patient with multiple myeloma. The protein was isolated by starch block electrophoresis and further purified by column chromatography on Sephadex G-200.
Eluates from the first half of the first peak were combined and concentrated. This material contained less than 1%
IgG. The antiserum obtained with this antigen was absorbed with umbilical cord sera to make it specific for a chains.
Antisera specific for K and X light-chains were prepared by hyperimmunizing rabbits to K and X Bence Jones proteins. These proteins were isolated from the urine of patients with multiple myeloma by mixing 3 Clotting factor activities were removed from antisera and from normal rabbit serum as follows: one part of citrate anticoagulant was added to five parts of serum; the serum was heated at 560C for 30 min; and the heated serum was then adsorbed with aluminum hydroxide gel (Cutter Laboratories, Berkeley, Calif.) diluted 1: 4 with distilled water (0.1 ml of gel per ml of serum). After such treatment all sera were devoid of significant clotting factor activities.
To interpret neutralization experiments one must have defined the zone of antigen, and antibody excess for the reaction mixtures, which in our experiments were mixtures of the immunoglobulin antisera and the patient's plasma containing the inhibitor. Therefore, the patient's plasma was diluted in increasing amounts of each immunoglobulin antisera, incubated at 370C for 1 hr, centrifuged, and the supernatant of each mixture was reacted in double diffusion in agar against the patient's plasma (antigen) and the antiserum (antibody) . If the supernatant reacted with the patient's plasma but not with the antiserum, then the original dilution was in antibody excess. If the supernatant reacted with the antiserum but not with the patient's plasma, then the dilution was in antigen excess. If the supernatant reacted with neither the patient's plasma nor the antiserum, then the dilution was near the equivalence point. 14 ,500 Somogyi units (N < 500).
He received isotonic electrolyte solutions, plasma, and blood. Because of continuing fever and arteriographic findings consistent with a pseudocyst of the head of the pancreas, he underwent exploratory surgery on September 2. A pancreatic pseudocyst was drained externally, and a gastroenterostomy was performed. The estimated blood loss was 700 ml. He received 1 U of blood during surgery.
The wound edges did not bleed excessively in the postoperative period. However, 4 days postoperatively he bled massively from the upper gastrointestinal tract. He was reoperated upon on September 8, and a bleeding artery at the gastroenterostomy site was ligated. Again, hemostasis at surgery was easily achieved, and excessive postoperative oozing was not noted. As a result of the complications described above, he received a total of 12 U of plasma and 20 U of whole blood between August 10 and September 14.
Bleeding attributable to a hemorrhagic disorder was first noted on September 14 when a large hematoma formed at the site of insertion of a femoral vein catheter.
Surgical exploration disclosed only generalized oozing. On September 16 a long clotting time was discovered, and the clotting studies, which will be described, revealed an anticoagulant against factor V. The anticoagulant was still present in blood drawn on September 23, but it was no longer present in blood drawn on September 29. Between September 13 Table I ) established the presence of a factor V anticoagulant. The hematochezia continued during the remainder of his hospital course, and he received 18 transfusions. After discovery of the factor V anticoagulant, he was transfused only with concentrated red blood cells and albumin. Despite the anticoagulant, excessive bleeding was not noted around the abdominal wound. On June 9 his condition deteriorated rapidly, and he died. An autopsy revealed a large hematoma underlying the surgical wound and extending to the peritoneal surface. The bowel wall was necrotic at the site of the anastomosis. Other findings included a small left subhepatic abscess and a metastatic nodule of adenocarcinoma in the lung.
RESULTS
Initial clotting studies. The results of our screening clotting tests on these patients are summarized in the upper part of Table I . The marked prolongation of both the partial thromboplastin time and the Quick prothrombin time and the failure of normal plasma to correct both tests indicated that an anticoagulant was interfering with both intrinsic and extrinsic clotting. Since factor V deficiency does not affect the prothrombin time by the The reaction between increasing dilutions of the anticoagulant and factor V over time. Increasing dilutions of each patient's plasma were incubated at room temperature with normal plasma; and at i, 15, and 30 min, subsamples were assayed for factor V activity (Fig. 1) 2) and in the second peak on Sephadex G-200 chromatography (Fig. 3) . All of these physicochemical properties suggested that the anticoagulants were immunoglobulins.
Neutralization of anticoagulant activity by immune precipitation. The basic plan for these experiments was to mix the patients' plasmas with different antisera and then to test the supernatant of the mixture for the presence or absence of inhibitor activity. For each experiment to be interpretable two conditions had to be met. (a) The patient's plasma had to be diluted in each particular antisera to equivalence or antibody excess. (b)
Inhibitor activity had to be present when this same dilution of the patient's plasma was made in control normal rabbit sera (nonspecific loss of inhibitor activity in control sera could be due to the following two processes:
[a] dilution or [b] antigenic determinants of factor V in the rabbit sera). Tables III and IV. Table II summarizes the results of neutralization experiments using rabbit antihuman immunoglobulin antiserum. As the data illustrate, this procedure removed all evidence of anticoagulant activity in both patients' plasmas and established that the anticoagulants were immunoglobulins.
The experiment was then repeated with antisera specific for av, a, and A chains in an attempt to define the immunoglobulin class of the anticoagulants. In patient No. 2 it was possible to show that the anti-y chain antiserum completely removed the anticoagulant activity from the patient's plasma, whereas the anti-a and anti-Is chain antisera did not remove the anticoagulant activity (Table III) . Therefore, the anticoagulant in patient No. 2 was an immunoglobulin of the IgG class. In patient No. 1, however, it was only possible to
show that the anti-is chain antiserum did not remove the anticoagulant activity (Table IV) . It was not possible to determine the effect of the anti-y or the anti-a chain antisera because the dilution of the patient's plasma in these specific antisera required for equivalence was sufficient in itself to dilute out the inhibitor activity. For example, a 1:10 dilution of the patient's plasma in antiserum was required to remove all of the IgA in the patient's plasma; this same dilution in normal rabbit serum (control) resulted in loss of anticoagulant activity. (Table IV) , but at the dilution of the patient's plasma in anti-K antiserum required to reach equivalence, anticoagulant activity was also lost from control dilutions in normal rabbit serum.
In patient No. 2, however, light chains could be typed. Antisera specific for either K or X chains failed to remove anticoagulant activity from the patient's plasma. Antisera made against Fab fragment, which contains antibodies against both antigenic types of light chains, completely removed the activity (Table IV) . Therefore, the inhibitor in patient No. 2 consisted of IgG molecules, some of which contained K chains and some of which contained X chains.
Inhibition of heterologous, homologous, and autologous factor V. Since rabbit, dog, and ox plasmas contain much more factor V activity than human plasma, each was diluted with citrated saline to a factor V activity equivalent to that of undiluted human plasma. These diluted plasmas were then incubated with the inhibitors, and subsamples were assayed for factor V activity. Both anticoagulants inhibited factor V activity in all three species to about the same degree as in man. Conceivably, the patients had an allotype of factor V that differed from the factor V in the blood with which they were transfused. If so, the anticoagulant could be an antibody directed against the transfused factor V and might react more strongly with factor V from other individuals than with the patient's own factor V. This could be tested only with patient No. l's factor V, since patient No. 2 died while his plasma still contained po- tent anticoagulant activity which prevented use of his plasma as a source of autologous factor V. Dilutions of patient No. l's plasma containing his factor V anticoagulant were incubated with dilutions of his plasma after the anticoagulant had disappeared (autologous factor V) and with dilutions of a normal pooled plasma prepared from 10 individuals (homologous factor V). The mix- (Table V) . However, at a 1: 10 dilution more factor V activity was present after incubation in the patient's recovery plasma than in the pooled normal plasma. Although the difference was small, it was observed each of the three times that the experiment was performed. Thus, the anticoagulant in patient No. 1 appeared to inhibit homologous factor V slightly more effectively than autologous factor V. Unfortunately, we ran out of recovery plasma from patient No. 1 and so could not study the effect of the anticoagulant in patient No. 2 upon patient No. l's factor V, as compared with homologous factor V in pooled plasma. Inhibition of platelet factor V activity and plasma factor V activity altered by exposure to thrombin or Russell's viper venom. Platelets contain factor V activity bound to the platelet membrane, which has been shown to be adsorbed plasma factor V (18). The platelets from 20 ml of fresh normal blood were separated by differential centrifugation, washed three times in 30 ml of buffered saline, and resuspended to a final volume of 3 ml in the same fluid. The platelet suspension, 0.5 ml, was then incubated with an equal volume of either hereditary factor V deficiency plasma (control) or patients' plasmas. At the end of 30 min, the platelets which had been incubated with factor V deficiency plasma had a factor V activity of 11%. In contrast, the platelets which had been incubated with either patient No. l's plasma or patient No. 2's plasma had a factor V activity of 1%. Thus, the anticoagulant inhibited factor V activity bound to platelets.
Dilute thrombin and Russell's viper venom interact with human factor V to increase factor V reactivity as measured in one-stage factor V assays with brain thromboplastin (19) . The alterations in the factor V molecule induced by these agents did not prevent loss of factor V activity upon incubation with either anticoagulant. For example, in one experiment one part of 1 u/ml bovine thrombin, prepared as described elsewhere (20) , was added to nine parts of oxalated human plasma that had been adsorbed with barium sulfate powder. Clotting times in the factor V assay of diluted subsamples shortened from 45 sec, when barbital buffer was used as the control for the thrombin, to [35] [36] [37] [38] sec. An equal volume of either adsorbed herditary factor V deficiency plasma, as a control, or adsorbed patient's plasma was added to the thrombin-treated factor V, and serial subsamples were removed, diluted, and assayed for factor V activity. The clotting times did not lengthen in the subsamples from the mixture containing hereditary factor V deficiency plasma, but they lengthened to 60-75 sec in the subsamples from the mixtures containing each patient's plasma. Similar data were obtained when a 100 ttg/ml solution of Russell's viper venom was substituted for the thrombin.
The inhibition of intrinsic prothrombin activator. There was a profound effect of the anticoagulant from both patients upon the generation of intrinsic prothrombin activator in the thromboplastin generation test. As expected, when either patient's blood was the source of the adsorbed plasma, the serum, or both, the incubation mixture failed to generate intrinsic prothrombin activator normally.
Intrinsic prothrombin activator generated from normal reagents clotted normal plasma, hereditary factor V deficiency plasma, and the patients' plasmas in identical times. Since factor V is required for the effective activity of intrinsic prothrombin activator (21) (22) (23) had not provided time enough for the anticoagulant in the patients' plasmas to act, or that these anticoagulants could not inhibit factor V after its incorporation into fully formed intrinsic prothrombin activator. Therefore, an experiment was designed in which intrinsic prothrombin activator generated from normal reagents was incubated with the patients' sera or with normal serum (control). Subsamples were removed at increasing intervals and tested for residual prothrombin activator activity by comparing their ability to clot normal plasma and hereditary factor V deficiency plasma. The data for patient No. 1 are illustrated in Fig. 4 . Note first that when prothrombin activator was incubated with normal serum, subsamples taken over the next 20 min gave the same clotting times for normal plasma as for hereditary factor V deficiency plasma. Thus, the activity persisting in the mixture was intrinsic prothrombin activator. Intermediates did not contribute significantly to the residual clotting activity. However, when prothrombin activator was incubated with patient No. l's serum, clotting activity was progressively lost for the normal plasma substrate and, to a striking degree, for the hereditary factor V deficiency plasma substrate. Similar results were obtained with patient No. 2's serum. This experiment clearly established that the inhibitors reacted over time with intrinsic prothrombin activator and confirms that factor V is required for the effective action of the intrinsic prothrombin activator.
Anticoagulant consumption studies. Since both anticoagulants were shown to be immunoglobulins that were consumed in the process of inhibiting factor V clotting activity, we next determined if incubation with factor V antigenic material without clotting activity would also consume the anticoagulants. In preliminary experiments, a dilution of each patient's plasma in normal plasma was found which, after incubation for 30 min, gave complete consumption of the anticoagulant as evidenced by no further inhibition of factor V activity when more normal plasma was added. In subsequent experiments this dilution of the patient's plasma was incubated with material being tested for factor V antigenic determinants. After 30 min, normal plasma was added to supply factor V, and the mixture was tested over time for residual factor V activity.
The data for patient No. 1 are summarized in Fig. 5 . Note first that incubation with normal plasma completely consumed the anticoagulant (line 4), whereas incubation with citrated saline failed to consume the anticoagulant (line 1). Incubation with human serum, which possessed no factor V clotting activity, also consumed the anticoagulant completely (line 3) and resulted in clotting times similar to those obtained with plasma. We interpret these data to mean that the anticoagulants had combined with factor V antigenic ma- terial without clotting activity and that such antigenic determinants were present in serum.
Having established that factor V antigenic material without clotting activity would consume the anticoagulant, we then incubated each anticoagulant with plasma from two patients with hereditary factor V deficiency (parahemophilia), one of whom was Owren's original patient (1) . Hereditary factor V deficiency plasmas consumed very little anticoagulant activity (line 2). Identical results were obtained with anticoagulant from patient No. 2. Therefore, the plasma of each of these patients with hereditary factor V deficiency not only lacks factor V activity but also lacks antigenic material of an inactive factor V capable of consuming these anticoagulants.
DISCUSSION
The above data establish that an anticoagulant against factor V was associated with a transient but serious hemorrhagic diathesis in patient No. 1 and serious bleeding in patient No. 2. These anticoagulants appeared to react stoichiometrically with human and other animal factor V in vitro and had the physicochemical characteristics of immunoglobulins. Neutralization of their activity with antihuman immunoglobulin antiserum established that they were both immunoglobulins. Owren's original studies indicated that factor V participates in prothrombin activation (27) , and recent evidence suggests that the prothrombin activator is a complex of activated factor X, factor V, and lipid in the presence of calcium ions (21) (22) (23) ). Ferguson, Johnston, and Howell (24) found that intrinsic prothrombin activator formed from normal reagents gave an abnormal thromboplastin generation test with substrate plasma from their patient with a factor V anticoagulant, which would support this hypothesis. The normal values we found when we did the same experiment were unexpected, and they illustrate a pitfall in test systems for evaluating the site of action of an anticoagulant in which powerful coagulant activity may clot a test mixture before an inhibitor has time to act. Thus, when the experiment was redesigned to allow time for the factor V anticoagulants to react with intrinsic prothrombin activator (Fig. 4) , marked inhibition was observed. Our data, therefore, confirm that factor V is required for the effective activity of intrinsic prothrombin activator.
The anticoagulants were immunoglobulins whosq activity was consumed not only when they were incubated with plasma containing factor V molecules that had clotting activity, but also when they were incubated with human serum that had no factor V clotting activity (Fig. 5 ). This experiment established that factor V antigenic material that had lost its clotting activity could still consume inhibitor activity. In contrast, incubation of the anticoagulants with plasma from two patients with hereditary factor V deficiency, one of whom was Owren's original patient (1), failed to consume anticoagulant activity. This indicates that in these patients hereditary factor V deficiency (parahemophilia) represents a true deficiency of factor V molecules rather than the synthesis of a molecule in which a minor structural change results in a loss of clotting activity. This does not eliminate the possibility that other patients with hereditary factor V deficiency may synthesize an abnormal molecule such as has been demonstrated in a minor population of patients with hemophilia A and hemophilia B (28) (29) (30) (31) (32) .
The reason our patients suddenly started making an immunoglobulin with factor V anticoagulant activity is unknown. Thrombocytopenia, secondary to platelet isoimmunization, is an uncommon but well-documented cause for purpura following transfusions (33, 34) . Perhaps the factor V anticoagulants in our patients represent an analogous phenomenon of isoimmunization to a clotting factor after transfusion. In support of this is the fact that four of the five patients with factor V inhibitors received transfusions prior to the development of a bleeding diathesis, and three of five inhibitors were present for a relatively short period of time.
The identification in patient No. 2 of anticoagulant molecules with both light-chain types supports the hypothesis of isoimmunization, because it suggests antibody production by many clones. The rapid disappearance of the anticoagulant in patient No. 1 and its suggestively greater effectiveness against homologous rather than autologous factor V (Table V) also fit with isoimmunization.
These findings contrast strikingly with the accumulating evidence of the monotypic nature of the lightchain types of high titer factor VIII inhibitors, which rarely disappear (35) (36) (37) .
Bleeding in previously normal individuals because of the formation of an immunoglobulin that inhibits the activity of a hemostatic factor has been described for platelets, for factor VIII, and now for factor V. The transient nature of the anticoagulant in patient No. 1 and our discovery of two cases within 1i yr lead us to suspect that factor V anticoagulants are not as rare as past documented experience would suggest. As patients with acquired anticoagulants are studied carefully, the evidence grows that the synthesis of immunoglobulins reacting with clotting factors is a major pathogenetic mechanism for acquired hemorrhagic disease in man.
